TD Asset Management
FRTX

TD Asset Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

TD Asset Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-28
Closed -$279K – 1274
2013
Q2 		$279K Buy
+28
New +$310K ﹤0.01% 1056

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Litespeed Management New York $48.2M AUM 9.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

TD Asset Management's FRTX Position: Q3 2013 in Review

TD Asset Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2013, closing a stake of 28 shares — an estimated $279K sold.

TD Asset Management first reported a position in FRTX in Q2 2013 and held it in 1 quarter. The position peaked at $279K in Q2 2013. 83 funds tracked by Wall St. Rank hold FRTX as of Q3 2013.

  • TD Asset Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • TD Asset Management sold 28 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2013, an estimated $279K.
  • TD Asset Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • TD Asset Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $279K in Q2 2013.
  • 83 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2013.

Based on TD Asset Management's 13F filing for Q3 2013, filed 8 Nov 2013.